

Supplementary Methods:

Study Recruitment: BioMe biobank participants identified for recall for the current study were contacted by both mail and email, with up to two attempts for each modality. If no response was received, then participants were contacted by telephone, with multiple repeated attempts per individual. Recontact was paused if a participant directly expressed a lack of interest in the study, or if after six failed attempts at reaching the participant by phone, at variable days and timepoints.

EHR/Chart Review: For the current study, a chart review of each participant enrolled in the study was conducted (by one board-certified psychiatrist RB) to confirm group assignment (i.e. schizophrenia or control) as well as overall medical history, including records from January 1, 2005, until the start of current study, November 12, 2020. Elements of charts reviewed included inpatient and outpatient clinical encounter notes as well as procedure notes and medication prescription records.

EHR Visit Density: Visit density was calculated as the sum of clinical encounters with a healthcare provider from January 1, 2005 until the start date of current study, November 12, 2020, with inpatient and outpatient encounters each counted as one visit. Only completed visits were included in the visit density calculation.

Clinical Assessment: The clinical assessment consisted of a structured diagnostic interview, the Mini International Neuropsychiatric Interview (MINI 7.0.2), compatible with DSM-5 and ICD-10 criteria.¹ In addition, an unstructured clinical interview was conducted consisting of a medical history (to corroborate EHR-derived medical history), additional psychiatric history (i.e. medication intake and hospitalizations), a retrospective development history to specifically query developmental milestones, learning difficulties, and history of special education, as well as a social and occupational history to assess functional status.

Neurocognitive Assessment: The neurocognitive battery consisted of seven sub-tests: the Digit Span Test to assess attention and executive function, comprised of three subtests, (i) Digit Span Forward, (ii) Digit Span Backward, and (iii) Digit Span Sequencing; (iv) Category fluency to assess processing speed and semantic memory; (v) Mayer-Salovey-Caruso Emotional Intelligence Test - Managing Emotions branch (MSCEIT-ME) to assess social cognition; and the Hopkins Verbal Learning Test – Revised (HVLT-R), (vi) immediate and (vii) delayed recall to assess verbal learning and memory.^{2, 3} The MSCEIT was scored using the Mayer-Salovey-Caruso Emotional Intelligence Test software.⁴

Remote Assessment Platform: Each of two 30-minute assessments was conducted at two variable, non-contiguous timepoints, and scheduled as per participant preference. Of the 73 participants who completed both study assessments, 79% were completed by phone and 21% by Zoom. The method of remote assessment, phone or Zoom platform, was selected as per patient preference, though most participants in the study opted for phone (60% of NDD CNV carriers, 95% of schizophrenia group and 91% of controls).

Remote Assessment Justification: Since the COVID-19 pandemic an increasing body of literature has informed on the validity of remote administration of neurocognitive testing generally and for the specific tests incorporated in the current study.⁵⁻¹² We followed published tele-practice recommendations for administering subtests of WAS-IV.¹³

Ranks of CNV Loci: For ranks of cognitive performance of NDD CNV carriers (Supplementary Table 6, Supplementary Figure 1) scores for Digit Span tests and HVLT-R were adjusted, based on age, sex, race/ethnicity, and education. Scores for Fluency and MSCEIT were adjusted for age, sex and

education. Cognitive score standardization was performed through the scoring platforms for each cognitive test (i.e. PARiConnect for HVLt-R, QGlobal for Digit Span, and the MBBC scoring kit for Fluency and MSCEIT-ME).^{14,15,16}

SUPPLEMENTARY REFERENCES

1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry*. 1998;59 Suppl 20:22-33;quiz 4-57.
2. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. *Am J Psychiatry*. 2008;165(2):203-13.
3. Wechsler D. Wechsler adult intelligence scale (WAIS-IV). San Antonio, TX2008.
4. Mayer JD, Salovey P, Caruso DR. Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT™). Toronto, Ontario: Multi-Health Systems; 2022.
5. Russell MT, Funsch KM, Springfield CR, Ackerman RA, Depp CA, Harvey PD, et al. Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness. *Schizophr Res Cogn*. 2022;27:100226.
6. Mahon S, Webb J, Snell D, Theadom A. Feasibility of administering the WAIS-IV using a home-based telehealth videoconferencing model. *Clin Neuropsychol*. 2022;36(3):558-70.
7. Brown T, Zakzanis K. A review of the reliability of remote neuropsychological assessment. *Applied Neuropsychology: Adult*. 2023:1-7.
8. Lavigne KM, Sauvé G, Raucher-Chéné D, Guimond S, Lecomte T, Bowie CR, et al. Remote cognitive assessment in severe mental illness: a scoping review. *Schizophrenia*. 2022;8(1):14.
9. Hays R, Henson P, Wisniewski H, Hendel V, Vaidyam A, Torous J. Assessing Cognition Outside of the Clinic: Smartphones and Sensors for Cognitive Assessment Across Diverse Psychiatric Disorders. *Psychiatr Clin North Am*. 2019;42(4):611-25.
10. Kilciksiz CM, Keefe R, Benoit J, Ongur D, Torous J. Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. *Schizophr Res Cogn*. 2020;21:100177.
11. Atkins AS, Kraus MS, Welch M, Yuan Z, Stevens H, Welsh-Bohmer KA, et al. Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. *Front Psychiatry*. 2022;13:910896.
12. Hamner T, Salorio CF, Kalb L, Jacobson LA. Equivalency of In-Person Versus Remote Assessment: WISC-V and KTEA-3 Performance in Clinically Referred Children and Adolescents. *J Int Neuropsychol Soc*. 2022;28(8):835-44.
13. Telepractice and the WAIS-IV: Pearson; [Available from: <https://www.pearsonassessments.com/content/dam/school/global/clinical/us/assets/telepractice/guidance-documents/telepractice-and-the-wais-iv.pdf>].
14. PAR I. HVLT-R Score Report n.d. [Available from: <https://www.parinc.com/Products/Pkey/130>].
15. Clinical P. Enter Scores for WISC-V n.d. [Available from: https://qglobal.pearsonclinical.com/qg/static/Product/es/WISC-V/WISC-V_Enter_Scores.htm].
16. PAR I. MCCB Kit n.d. [Available from: <https://www.parinc.com/Products/Pkey/225>].

Supplementary Table 1: Sample Demographics. Age, sex and ancestry of biobank participants who were recontacted and completed study.

	Biobank Participants (n=24,877)	NDD CNV (n=627)	RECONTACTED FROM BIOBANK				COMPLETED STUDY ASSESSMENTS				RECONTACTED vs COMPLETED, Statistics				
			NDD CNV (n=335)	Schizophrenia (n=217)	Controls (n=340)	Total (n=892)	NDD CNV (n=30)	Schizophrenia (n=20)	Controls (n=23)	Total (n=73)	NDD -CNV	SCZ	CONT		
Mean Age, Biobank Enrollment (SD)	50.5 (17.3)	50.4 (17.0)	39.0 (10.8)	45.4 (9.9)	41.9 (10.7)	41.5 (10.8)	37.3 [9.2]	41 [9.3]	39.9 [9.4]				t=0.87, p=0.39	t=2.03, p=0.07	t=0.85, p=0.38
Mean Age at Study Assessment (SD)							47.3 [9.5]	50.2 [10.1]	49.5 [11.2]	48.8 (10.2)					
Female (%)	14,586 (59%)	389 (62%)	219 (65%)	97 (45%)	209 (61%)	525 (59%)	26 (87%)	8 (40%)	14 (61%)	48 (66%)	X2=5.9, p=0.02	X2=0.1, p=0.78	X2=0.00, p=0.99		
Ancestry (%)							-	-	-		X2=1.4, p=0.70	X2=2.1, p=0.55	X2=2.8, p=0.43		
African	5965 (24%)	168 (27%)	95 (28%)	101 (47%)	111 (33%)	307 (34%)	10 (33%)	8 (40%)	8 (35%)	26 (36%)					
European	7892 (32%)	208 (33%)	102 (30%)	17 (8%)	52 (15%)	171 (19%)	10 (33%)	3 (15%)	7 (30%)	20 (26%)					
Hispanic	8536 (34%)	200 (32%)	109 (33%)	87 (40%)	151 (44%)	347 (38%)	9 (30%)	9 (45%)	7 (30%)	25 (34%)					
Other	2484 (10%)	51 (8%)	29 (9%)	12 (6%)	26 (8%)	67 (8%)	1 (3%)	0 (0)	1 (4%)	2 (3%)					

For statistical comparisons of recontacted and retained groups, chi-square values for sex and ancestry are indicated, and t-test for age. Ancestry is self-reported ancestry

Supplementary Table 2: NDD CNV Loci Prevalence, by CNV Locus. Counts of NDD CNV carriers, by CNV locus, with genomic coordinates (hg19).

NDD CNV	hg19 coordinates	Genes (n)	BioMe (n=627)	Recontacted (n=335)	Completed Study (n=30)	NDD CNV Prevalence: BioMe vs Completed Study (p-value)
TAR_del	chr1:145,39–145,81	17	5	2		
TAR_dup	chr1:145,39–145,81	17	18	8	3	2.29E-05
1q21.1del**	chr1:146,53–147,39	9	8	5	1	0.27
1q21.1dup	chr1:146,53–147,39	9	3	2	1	0.05
NRXN1_DEL**	chr2:50,14–51,26	1	3	1		
2q11.2del	chr2:96,74–97,68	22	2	1		
2q11.2dup	chr2:96,74–97,68	22	1	1		
2q13del(NPHP1)	chr2:110,86–110,98	3	81	38	2	0.70
2q13dup(NPHP1)	chr2:110,86–110,98	3	62	32	3	0.08
2q13del	chr2:111,39–112,01	3	3	3		
2q13dup	chr2:111,39–112,01	3	8	7		
2q21.1del	chr2:131,48–131,93	5	9	6		
2q21.1dup	chr2:131,48–131,93	5	5	3		
3q29del**	chr3:195,72–197,35	28	1	1		
3q29dup	chr3:195,72–197,35	28	0	0		
Sotos_5q35del	chr5:175,72–177,05	39	0	0		
5q35dup	chr5:175,72–177,05	39	0	0		
7q11.23_del	chr7:72,74–74,14	26	1	0		
7q11.23_dup	chr7:72,74–74,14	26	0	0		
7q11.23dup_distal	chr7:75,14–76,06	16	0	0		
8p23.1del	chr8:8,10–11,87	35	0	0		
8p23.1dup	chr8:8,10–11,87	35	0	0		
10q11.21q11.23del	chr10:49,39–51,06	19	1	0		
10q11.21q11.23dup	chr10:49,39–51,06	19	2	0		
10q23del	chr10:82,05–88,93	29	0	0		
10q23dup	chr10:82,05–88,93	29	1	0		
13q12del(CRYL1)	chr13:20,98–21,10	2	8	4		
13q12dup(CRYL1)	chr13:20,98–21,10	2	0	0		
13q12.12del	chr13:23,56–24,88	10	4	3		
13q12.12dup	chr13:23,56–24,88	10	9	3		
15q11.2del	chr15:22,81–23,09	5	60	27	5	8.01E-05
15q11.2dup	chr15:22,81–23,09	5	163	89	4	0.39
PW/AS_15q11.2q13.1 BP1-3_del	chr15:23,68–28,39	116	0	0		
PW/AS_15q11.2q13.1 BP1-3_dup	chr15:23,68–28,39	116	0	0		
15q11q13del_BP3-BP4(APBA2_TJP)	chr15:29,16–30,38	4	1	1		
15q11q13dup_BP3-BP4(APBA2_TJP)	chr15:29,16–30,38	4	3	1		
15q11q13dup_BP3-BP5	chr15:29,16–32,46	17	0	0		
15q13.3del	chr15:31,08–32,46	8	5	0		
15q13.3dup	chr15:31,08–32,46	8	5	2		
15q13.3del(CHRNA7)	chr15:32,02–32,46	1	5	2		
15q13.3dup(CHRNA7)	chr15:32,02–32,46	1	42	19	2	0.23
15q24del	chr15:72,90–78,15	77	0	0		
15q24dup	chr15:72,90–78,15	77	0	0		
16p13.11del	chr16:15,51–16,29	7	13	4	2	3.35E-03
16p13.11dup	chr16:15,51–16,29	7	39	19	2	0.19
16p12.1del	chr16:21,95–22,43	8	2	0		
16p12.1dup	chr16:21,95–22,43	8	14	7		
16p11.2distal_del**	chr16:28,82–29,05	11	5	4	1	0.13
16p11.2distal_dup	chr16:28,82–29,05	11	4	3		
16p11.2del	chr16:29,65–30,20	30	15	12	1	0.53
16p11.2dup**	chr16:29,65–30,20	30	4	4		
17p12del	chr17:14,14–15,43	8	6	5	1	0.18
17p12dup	chr17:14,14–15,43	8	10	7		
Smith Magenis Syndrome_17p11.2del	chr17:16,81–20,21	59	0	0		
Potocki-Lupski syndrome_17p11.2dup	chr17:16,81–20,21	59	0	0		
17q11.2del(NF1)	chr17:29,12–30,27	19	0	0		
17q11.2dup(NF1)	chr17:29,12–30,27	19	0	0		
17q12del	chr17:34,81–36,22	17	4	2		
17q12dup	chr17:34,81–36,22	17	4	2		
17q21.31del	chr17:43,70–44,29	10	0	0		
22q11.2del**	chr22:19,04–21,47	61	1	1	1	3.46E-03
22q11.2dup	chr22:19,04–21,47	61	7	4	1	0.22
22q11.2distal_del	chr22:21,92–23,65	26	0	0		
22q11.2distal_dup	chr22:21,92–23,65	26	0	0		

p-value is a test of equal proportions comparing the prevalence of each NDD CNV locus in the subset that completed the study with overall BioMe prevalence

**=NDD CNV loci previously reported to be significantly associated with schizophrenia by GWAS (Marshall CR, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49(1):27-35)

Supplementary Table 3: Psychiatric Symptomatology of NDD CNV carriers. Mood and anxiety disorders of NDD CNV carriers, as identified in clinical assessment.

NDD CNV LOCI	COUNT	Mood or Anxiety Disorder (n)	Mood/Anxiety Disorder (MINI)	Diagnostic Concordance of MINI SCALE with EHR-derived
TAR dup	3	1	Bipolar Disorder with Psychotic Features	Yes
1q21.1del	1	1	Major Depressive Disorder, Generalized Anxiety Disorder, Panic Attacks	Yes
1q21.1dup	1	1	Obsessive Compulsive Disorder	Yes
2q13dup(NPHP1)	3	2	Obsessive Compulsive Disorder (n=1); Panic Disorder and PTSD (n=1)	No
15q11.2dup	4	2	Generalized Anxiety Disorder (n=1), Major Depressive Disorder (n=1)	No
15q13.3dup(CHRNA7)	2	1	Major Depressive Disorder	Yes
16p11.2distal_del	1	1	Posttraumatic Stress Disorder, Generalized Anxiety Disorder	No
16p13.11del	2	2	Generalized Anxiety Disorder (n=1), Major Depressive Disorder (n=1)	Yes
16p13.11dup	2	1	Major Depressive Disorder	Yes

Notes: Count is number of individuals who completed the study, by locus

Supplementary Table 4: NDD CNVs, Medical Comorbidities. Medical co-morbidities by NDD CNV locus that were previously reported.

CNV locus	Location (hg19)	Significant medical phenotypes (UK Biobank)*	Other Phenotypes (Other Reports)*	Source/Reference
TAR_dup	chr1:145,39-145,81	Obesity	Skeletal/facial dysmorphia, ophthalmological	Rosenfeld et al, 2012 (PMC3376272)
1q21.1del	chr1:146,53-147,39	Cataract, Heart failure	Short stature, cardiac, cataracts, microcephaly	OMIM; Brunetti-Pieri et al, 2008 (PMID:19029900)
1q21.1dup	chr1:146,53-147,39	Type 2 Diabetes	Short stature, scoliosis, gastric ulcers, macrocephaly	OMIM; Brunetti-Pieri et al, 2008 (PMID:19029900)
2q13del(NPHP1)	chr2:110,86-110,98	n/a	Nephronophthisis 1	OMIM
2q13dup(NPHP1)	chr2:110,86-110,98	n/a	-	-
15q11.2del	chr15:22,81-23,09	n/a	Neurological Dysfunction	OMIM, Cox & Butler, 2015 (PMC4346944)
15q11.2dup	chr15:22,81-23,09	n/a	-	-
15q13.3dup(CHRNA7)	chr15:32,02-32,45	n/a	-	-
16p13.11del	chr16:15,51-16,29	n/a	-	-
16p13.11dup	chr16:15,51-16,29	Hypertension	-	-
16p11.2distal_del	chr16:28,82-29,05	Gout, Obesity, Type 2 Diabetes	Obesity	Bachmann-Gagescu et al, 2010 (PMID:20808231)
16p11.2del	chr16:29,65-30,20	Type 2 Diabetes, Obesity, Anemia, Asthma, Renal Failure, Hypertension, Osteoarthritis	Congenital abnormalities, seizures, eye accommodation, obesity	Shinawi et al, 2009 (PMID19914906); Jacquemont et al, 2011 (PMC3637175)
17p12del(HNPP)	chr17:14,14-15,43	Neuropathies	HNPP (Hereditary neuropathy with liability to pressure palsies)	Lupski et al, 1992 (PMID:1301995)
22q11.2del	chr22:19,04-21,47	n/a	VCFS/DGS, multiple phenotypes	OMIM; McDonald-McGinn et al, (PMID:27189754)
22q11.2dup	chr22:19,04-21,47	Hernia, Gastric Reflux, Aneurysm	Hypotonia, seizures, vision, hearing, heart defects	Wentzl et al, 2008 (PMID18707033)

BioMe CNV Sample (n)	Medical phenotypes identified in BioMe sample, also reported as significant in UK Biobank	Medical phenotypes identified in BioMe, also noted in other reports
3	Obesity	Obesity
1	No Overlap	No Overlap
1	No Overlap	Gastric Ulcers
2	-	No Overlap
3	-	-
5	-	No Overlap
4	-	-
2	-	-
2	-	-
2	Hypertension	No Overlap
1	Obesity	Obesity
1	Obesity, Hypertension	Obesity, Hypertension
1	Neuropathy	No Overlap
1	-	Cardiac Anomaly, Thrombocytopenia
1	No Overlap	No Overlap

Phenotypes for current sample was obtained by chart review and confirmed during clinical interview by patient self-report

Complete medical histories of NDD CNV carriers are not tabulated, but rather only conditions that overlap previously reported, latter 2 columns

Significant medical phenotypes in UKBB were reported at FDR threshold of 0.1

*As previously reported in Crawford K, Bracher-Smith M, Owen D, Kendall KM, Rees E, Pardiñas AF, et al. Medical consequences of pathogenic CNVs in adults: analysis of the UK Biobank. *J Med Genet.* 2019;56(3):131-8

Supplementary Table 5: Cognitive Effects of NDD CNVs: Results of regressing seven cognitive scores against group status.

NDD CNV (n=30) compared to schizophrenia (n=20) and controls (n=23)								
Cognitive Test	β		t-value		p-value		FDR	
	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia
DigitSpan_Forward	1.06	-2.04	1.45	-2.53	0.15	0.01	0.36	0.03
DigitSpan_Backward	1.28	-1.96	1.89	-2.63	0.06	0.01	0.22	0.03
DigitSpan_Sequencing	1.68	-1.39	2.30	-1.72	0.02	0.09	0.17	0.16
HVLTR_Total	1.07	-5.05	0.75	-3.20	0.46	0.00	0.54	0.01
HVLTR_Delayed	0.55	-0.78	0.74	-0.96	0.46	0.34	0.54	0.34
Fluency	1.50	-2.89	0.77	-1.34	0.45	0.18	0.54	0.21
MSCEIT-ME	0.90	-3.14	0.48	-1.50	0.64	0.14	0.64	0.19

Reference group: CNV

NDD CNV subset (n=22) compared to schizophrenia (n=20) and controls (n=23)								
Cognitive Test	β		t-value		p-value		FDR	
	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia
DigitSpan_Forward	1.10	-2.00	1.41	-2.38	0.16	0.02	0.29	0.07
DigitSpan_Backward	1.76	-1.54	2.57	-2.08	0.01	0.04	0.04	0.10
DigitSpan_Sequencing	2.01	-1.10	2.60	-1.33	0.01	0.19	0.04	0.27
HVLTR_Total	1.69	-4.50	1.14	-2.79	0.26	0.01	0.36	0.05
HVLTR_Delayed	0.80	-0.57	0.99	-0.66	0.33	0.51	0.38	0.51
Fluency	2.82	-1.73	1.44	-0.82	0.16	0.42	0.29	0.49
MSCEIT-ME	0.63	-3.37	0.31	-1.53	0.76	0.13	0.76	0.23

Reference group: CNV

Schizophrenia (n=20) vs Controls (n=23)				
Cognitive Test	β	t-value	p-value	FDR
DigitSpan_Forward	-3.10	-3.89	2.30E-04	4.56E-04
DigitSpan_Backward	-3.24	-4.40	3.99E-05	2.79E-04
DigitSpan_Sequencing	-3.07	-3.86	2.60E-04	4.56E-04
HVLTR_Total	-6.12	-3.93	2.02E-04	4.56E-04
HVLTR_Delayed	-1.33	-1.65	0.10	0.10
Fluency	-4.39	-2.07	0.04	0.06
MSCEIT-ME	-4.03	-1.97	0.05	0.06

Reference group: Controls

Note: Cognitive scores were regressed against group while covarying for age, sex, and ancestry.

Supplementary Table 6. Cognitive Test Performance Rank, by NDD CNV Locus. Rank of cognitive scores of each NDD CNV carrier.

NDD CNV Locus	Overall_Rank	Digit Span Forward	Digit Span Backward	Digit Span Sequencing	HVLT-R Immediate	HVLT-R Delayed	Fluency	MSCEIT-ME
1q21.1 dup	1	6	2	1	8	2	2	6
15q13.3 dup (CHRNA7)	2	3	1	2	10	12	1	25
22q11.2 dup	3	1	14	6	19	12	9	4
16p11.2distal del	4	11	19	6	2	12	10	8
16p13.11 dup (2)	5	19	9	19	3	1	16	6
15q13.3 dup (CHRNA7) (2)	6	17	9	12	1	12	14	10
TAR dup	7	11	14	12	14	5	4	20
2q13 del (NPHP1)	8	11	14	6	8	12	19	18
16p13.11 del (2)	9	6	19	6	4	17	12	26
2q13 dup (NPHP1) (3)	10	17	9	19	12	18	5	14
2q13 del (NPHP1) (2)	11	22	4	19	9	5	8	28
15q11.2 del (5)	12	17	19	23	8	6	7	16
17p12 del	13	17	19	19	8	5	4	25
16p13.11 dup	14	6	9	19	16	23	23	7
2q13 dup (NPHP1)	15	17	19	21	17	13	7	21
15q11.2 dup (4)	16	3	21	12	22	17	23	18
15q11.2 del (3)	17	17	9	12	14	19	28	20
15q11.2 dup (2)	18	26	21	25	19	12	14	9
15q11.2 dup (3)	20	11	14	12	22	30	25	22
16p13.11 del	20	22	27	19	24	30	11	3
15q11.2 dup	21	7	14	21	25	30	25	16
15q11.2 del	22	27	25	12	11	17	27	NA
TAR dup (2)	23	19	25	25	22	22	18	13
TAR dup (3)	24	22	25	27	16	14	18	28
15q11.2 del (4)	25	30	29	30	24	20	15	13
1q21.1 del	26	26	3	19	30	24	30	30
16p11.2 del	27	28	30	23	26	21	23	23
22q11.2 del	28	26	25	27	30	30	26	13
15q11.2 del (2)	29	26	29	30	30	30	23	NA
2q13 dup (NPHP1) (2)	30	30	27	30	30	30	30	29

Note: For ranking of Digit Span tests and HVLT-R, cognitive scores were adjusted for age, sex, race/ancestry and years of education . For ranking of Fluency and MSCEIT-ME A rank of '1' is highest performing and '30' is lowest (most impaired). See Supplementary Figure 1 for a plot of rankings, by NDD CNV carrier and by cognitive test

Supplementary Table 7: NDD CNV Loci, Alternative Set. NDD CNV carriers subset to include CNV loci in previous UKBB reports.

NDD CNV	hg19 coordinates	Genes (n)	Completed Assessment (n=30)	Alternative, Stringent Subset (n=22)
TAR_dup	chr1:145,39–145,81	17	3	3
1q21.1del	chr1:146,53–147,39	9	1	1
1q21.1dup	chr1:146,53–147,39	9	1	1
2q13del(NPHP1)	chr2:110,86–110,98	3	2	0
2q13dup(NPHP1)	chr2:110,86–110,98	3	3	0
15q11.2del	chr15:22,81–23,09	5	5	5
15q11.2dup	chr15:22,81–23,09	5	4	4
15q13.3dup(CHRNA7)	chr15:32,02–32,46	1	2	0
16p13.11del	chr16:15,51–16,29	7	2	2
16p13.11dup	chr16:15,51–16,29	7	2	2
16p11.2distal_del	chr16:28,82–29,05	11	1	1
16p11.2del	chr16:29,65–30,20	30	1	1
17p12del	chr17:14,14–15,43	8	1	0
22q11.2del	chr22:19,04–21,47	61	1	1
22q11.2dup	chr22:19,04–21,47	61	1	1

Supplementary Table 8: NDD CNV Cognitive Effects, Alternative model. Regression results of cognitive scores, including education as additional covariate

NDD CNV (n=30) compared to schizophrenia (n=20) and controls (n=23)								
Cognitive Test	β		t-value		p-value		FDR	
	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia
DigitSpan_Forward	0.905	-1.451	1.276	-1.776	0.206	0.080	0.481	0.188
DigitSpan_Backward	1.121	-1.355	1.727	-1.813	0.089	0.074	0.311	0.188
DigitSpan_Sequencing	1.494	-0.665	2.154	-0.832	0.035	0.408	0.244	0.715
HVLTTR_Total	0.456	-2.689	0.387	-1.985	0.700	0.051	0.806	0.188
HVLTTR_Delayed	0.271	0.283	0.417	0.378	0.678	0.706	0.806	0.824
Fluency	0.741	0.014	0.441	0.007	0.661	0.994	0.806	0.994
MSCEIT-ME	0.430	-1.040	0.246	-0.513	0.806	0.610	0.806	0.824


reference group: CNV

NDD CNV subset (n=22) compared to schizophrenia (n=20) and controls (n=23)								
Cognitive Test	β		t-value		p-value		FDR	
	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia	Controls	Schizophrenia
DigitSpan_Forward	0.814	-1.571	1.049	-1.847	0.299	0.070	0.697	0.245
DigitSpan_Backward	1.532	-1.194	2.239	-1.590	0.029	0.117	0.104	0.273
DigitSpan_Sequencing	1.696	-0.633	2.227	-0.758	0.030	0.451	0.104	0.632
HVLTTR_Total	0.573	-2.807	0.435	-1.944	0.665	0.057	0.851	0.245
HVLTTR_Delayed	0.224	0.294	0.310	0.372	0.757	0.711	0.851	0.830
Fluency	1.507	0.245	0.839	0.124	0.405	0.901	0.708	0.901
MSCEIT-ME	-0.369	-1.758	-0.189	-0.820	0.851	0.416	0.851	0.632

reference group: CNV


Note: Linear Regression results are derived from regressing each cognitive test against group status, while covarying for age, sex, and ancestry, and educational level

Supplementary Figure 2: Correlation of Cognitive Tests with Group Status. Plots demonstrating significant correlations of cognitive tests of social cognition with group and sex, and verbal learning with sex



Notes: x-axis is participants across comparator groups for each indicated category, and y-axis is cognitive test. See Table 1 for details, AFR (n=26); HISP (n=25), EUR (n=20); Female (n=48), Male (n=25).

Supplementary Figure 1: Cognitive Test Performance Rank, by NDD CNV Locus. The x-axis is NDD CNV locus and the y-axis is rank of cognitive performance, with a low rank indicating higher cognitive performance.



Notes: See Supplementary Table 6 for ranked loci in tabulated form. On x-axis, NDD CNV loci with more than one carrier are numerically numbered, such as (1), (2), (3). On y-axis, a rank of '1' is highest performing and '30' is lowest (most impaired)